Roche Gets FDA Approval for Cancer-Treatment Test
April 23 2021 - 6:47AM
Dow Jones News
By Matt Grossman
Roche Holding AG has gained approval from the U.S. Food and Drug
Administration for a diagnostic test used to determine whether
patients with endometrial cancer will benefit from a particular
treatment.
The test, called Ventana MMR RxDx, can help physicians decide
whether an endometrial cancer patient should be treated with
Jemperli, an anti-PD1 immunotherapy from GlaxoSmithKline PLC.
The test uses a comprehensive panel of DNA mismatch repair
biomarkers tested by immunohistochemistry, Roche said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 23, 2021 06:32 ET (10:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
